Carisma Therapeutics Inc. (CARM) - Net Assets
Based on the latest financial reports, Carisma Therapeutics Inc. (CARM) has net assets worth $-867.00K USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($6.55 Million) and total liabilities ($7.42 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check CARM intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-867.00K |
| % of Total Assets | -13.23% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | -247.32% |
| Growth Volatility | 493.16 |
Carisma Therapeutics Inc. - Net Assets Trend (2011–2024)
This chart illustrates how Carisma Therapeutics Inc.'s net assets have evolved over time, based on quarterly financial data. See Carisma Therapeutics Inc. defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Carisma Therapeutics Inc. (2011–2024)
The table below shows the annual net assets of Carisma Therapeutics Inc. from 2011 to 2024. For live valuation and market cap data, see market value of Carisma Therapeutics Inc..
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-27.91 Million | -205.19% |
| 2023-12-31 | $26.53 Million | +118.60% |
| 2022-12-31 | $-142.67 Million | -183.09% |
| 2021-12-31 | $171.71 Million | +1960.95% |
| 2020-12-31 | $-9.23 Million | +65.44% |
| 2019-12-31 | $-26.70 Million | -160.40% |
| 2018-12-31 | $44.21 Million | +145.13% |
| 2017-12-31 | $18.03 Million | -53.37% |
| 2016-12-31 | $38.68 Million | +104.16% |
| 2015-12-31 | $18.94 Million | -48.56% |
| 2014-12-31 | $36.83 Million | +1469.74% |
| 2013-12-31 | $2.35 Million | -59.12% |
| 2012-12-31 | $5.74 Million | +4004.08% |
| 2011-12-31 | $-147.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Carisma Therapeutics Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 28566700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $41.00K | % |
| Other Components | $277.63 Million | % |
| Total Equity | $-27.91 Million | 100.00% |
Carisma Therapeutics Inc. Competitors by Market Cap
The table below lists competitors of Carisma Therapeutics Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Ordinary Fully Paid Deferred Settlement
AU:HRZDB
|
$8.38K |
|
KRUNGTHAI CARD FGN BA 1
F:KRTA
|
$8.48K |
|
PTT Global Chemical Public Company Limited
F:GCB
|
$8.58K |
|
Yeh-Chiang Technology
TWO:6124
|
$8.66K |
|
Sorted Group Holdings Plc
LSE:SORT
|
$8.37K |
|
musicMagpie PLC
LSE:MMAG
|
$8.10K |
|
Fibra Mty S.A.P.I. de C.V.
MX:FMTY14
|
$7.77K |
|
SCG PACKAGING -FGN- BA 1
F:5Y7A
|
$7.68K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Carisma Therapeutics Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 26,532,000 to -27,909,000, a change of -54,441,000 (-205.2%).
- Net loss of 60,477,000 reduced equity.
- New share issuances of 2,392,000 increased equity.
- Other comprehensive income increased equity by 89,554,000.
- Other factors decreased equity by 85,910,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-60.48 Million | -216.69% |
| Share Issuances | $2.39 Million | +8.57% |
| Other Comprehensive Income | $89.55 Million | +320.88% |
| Other Changes | $-85.91 Million | -307.82% |
| Total Change | $- | -205.19% |
Book Value vs Market Value Analysis
This analysis compares Carisma Therapeutics Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | $-0.34 | $0.02 | x |
| 2012-12-31 | $16.13 | $0.02 | x |
| 2013-12-31 | $5.49 | $0.02 | x |
| 2014-12-31 | $50.30 | $0.02 | x |
| 2015-12-31 | $19.95 | $0.02 | x |
| 2016-12-31 | $35.58 | $0.02 | x |
| 2017-12-31 | $13.82 | $0.02 | x |
| 2018-12-31 | $14.31 | $0.02 | x |
| 2019-12-31 | $-5.87 | $0.02 | x |
| 2020-12-31 | $-1.56 | $0.02 | x |
| 2021-12-31 | $18.84 | $0.02 | x |
| 2022-12-31 | $-3.90 | $0.02 | x |
| 2023-12-31 | $0.79 | $0.02 | x |
| 2024-12-31 | $-0.67 | $0.02 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Carisma Therapeutics Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -308.05%
- • Asset Turnover: 0.64x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-143.12%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 0.00% | 0.00% | 0.00x | 0.00x | $-12.96 Million |
| 2012 | -345.44% | 0.00% | 0.00x | 1.66x | $-20.40 Million |
| 2013 | -828.01% | -1456.15% | 0.12x | 4.79x | $-19.66 Million |
| 2014 | -93.77% | -1539.55% | 0.04x | 1.49x | $-38.21 Million |
| 2015 | -176.58% | -3378.99% | 0.03x | 1.94x | $-35.35 Million |
| 2016 | 4.89% | 6.31% | 0.29x | 2.69x | $-1.98 Million |
| 2017 | -160.97% | -6830.35% | 0.01x | 4.16x | $-30.83 Million |
| 2018 | -76.22% | 0.00% | 0.00x | 2.52x | $-38.11 Million |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-104.83 Million |
| 2020 | 0.00% | -252.31% | 0.06x | 0.00x | $-27.43 Million |
| 2021 | -0.20% | -1.27% | 0.08x | 1.82x | $-17.51 Million |
| 2022 | 0.00% | -622.60% | 0.14x | 0.00x | $-45.52 Million |
| 2023 | -327.45% | -582.34% | 0.17x | 3.38x | $-89.53 Million |
| 2024 | 0.00% | -308.05% | 0.64x | 0.00x | $-57.69 Million |
Industry Comparison
This section compares Carisma Therapeutics Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $155,285,360
- Average return on equity (ROE) among peers: -101.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Carisma Therapeutics Inc. (CARM) | $-867.00K | 0.00% | N/A | $8.37K |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $83.17 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $-26.99 Million | 0.00% | 0.00x | $321.39 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $182.50 Million | -46.25% | 0.30x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $4.59 Million | -357.76% | 1.38x | $35.10 Million |
| Abivax SA American Depositary Shares (ABVX) | $33.94 Million | -14.97% | 0.12x | $7.98 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $113.93 Million | -49.49% | 0.18x | $3.66 Billion |
About Carisma Therapeutics Inc.
Carisma Therapeutics, Inc., a biotechnology company, focuses on developing transformative therapies to treat liver fibrosis and cancer in the United States. Its product candidates include CT-2401, which is in preclinical trial for the treatment of liver fibrosis. The company also develops CT-1119, a mesothelin-targeted CAR-Monocyte that is in phase I clinical trial to treat patients with advanced… Read more